PMID- 37419079
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20240322
IS  - 1872-6232 (Electronic)
IS  - 0378-3782 (Print)
IS  - 0378-3782 (Linking)
VI  - 183
DP  - 2023 Aug
TI  - Evaluation of neurovascular coupling during neuroprotective therapies: A single 
      site HEAL ancillary study.
PG  - 105815
LID - S0378-3782(23)00111-1 [pii]
LID - 10.1016/j.earlhumdev.2023.105815 [doi]
AB  - BACKGROUND: There is a critical need for development of physiological biomarkers 
      in infants with birth asphyxia to identify the physiologic response to therapies 
      in real time. This is an ancillary single site study of the High-Dose 
      Erythropoietin for Asphyxia and Encephalopathy (Wu et al., 2022 [1]) to measure 
      neurovascular coupling (NVC) non-invasively during an ongoing blinded randomized 
      trial. METHODS: Neonates who randomized in the HEAL enrolled at a single-center 
      Level III Neonatal Intensive Care Unit were recruited between 2017 and 2019. 
      Neurodevelopmental impairment was blinded and defined as any of the following: 
      cognitive score <90 on Bayley Scales of Infant Toddler Development, third edition 
      (BSID-III), Gross Motor Function Classification Score (GMFCS) >/=1. RESULTS: All 
      twenty-seven neonates enrolled in HEAL were recruited and 3 died before complete 
      recording. The rank-based analysis of covariance models demonstrated lack of 
      difference in NVC between the two groups (Epo versus Placebo) that was consistent 
      with the observed lack of effect on neurodevelopmental outcomes. CONCLUSION: We 
      demonstrate no difference in neurovascular coupling after Epo administration. 
      These findings are consistent with overall negative trial results. Physiological 
      biomarkers can help elucidate mechanisms of neuroprotective therapies in real 
      time in future trials.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Chalak, Lina F
AU  - Chalak LF
AD  - Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of 
      Texas Southwestern Medical Center, Dallas, TX, United States of America. 
      Electronic address: Lina.chalak@utsouthwestern.edu.
FAU - Kang, Shu
AU  - Kang S
AD  - Department of Bioengineering, University of Texas at Arlington, Arlington, TX, 
      United States of America.
FAU - Kota, Srinivas
AU  - Kota S
AD  - Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of 
      Texas Southwestern Medical Center, Dallas, TX, United States of America.
FAU - Liu, Hanli
AU  - Liu H
AD  - Department of Bioengineering, University of Texas at Arlington, Arlington, TX, 
      United States of America.
FAU - Liu, Yulun
AU  - Liu Y
AD  - Department of Population and Data Sciences, University of Texas Southwestern 
      Medical Center, Dallas, TX, United States of America.
FAU - Juul, Sandra E
AU  - Juul SE
AD  - Division of Neonatology, Department of Pediatrics, University of Washington 
      School of Medicine, Seattle, WA, United States of America.
FAU - Wu, Yvonne W
AU  - Wu YW
AD  - Department of Neurology, University of California San Francisco, San Francisco, 
      CA, United States of America.
LA  - eng
GR  - P50 HD103524/HD/NICHD NIH HHS/United States
GR  - R01 NS102617/NS/NINDS NIH HHS/United States
GR  - U01 NS092764/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230703
PL  - Ireland
TA  - Early Hum Dev
JT  - Early human development
JID - 7708381
RN  - 11096-26-7 (Erythropoietin)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Infant, Newborn
MH  - Infant
MH  - Humans
MH  - Asphyxia
MH  - *Neurovascular Coupling
MH  - *Asphyxia Neonatorum
MH  - Neuroprotection
MH  - *Erythropoietin/therapeutic use
MH  - Biomarkers
MH  - *Hypoxia-Ischemia, Brain/drug therapy
PMC - PMC10824020
MID - NIHMS1959338
OTO - NOTNLM
OT  - Erythropoietin
OT  - Hypoxic ischemic encephalopathy
OT  - Neuroprotective therapy
OT  - Neurovascular coupling
OT  - Physiological biomarker
COIS- Declaration of competing interest The authors have no conflicts or any competing 
      interest to disclose.
EDAT- 2023/07/08 10:42
MHDA- 2023/10/23 00:41
PMCR- 2024/01/29
CRDT- 2023/07/07 18:11
PHST- 2023/05/05 00:00 [received]
PHST- 2023/06/26 00:00 [revised]
PHST- 2023/06/27 00:00 [accepted]
PHST- 2023/10/23 00:41 [medline]
PHST- 2023/07/08 10:42 [pubmed]
PHST- 2023/07/07 18:11 [entrez]
PHST- 2024/01/29 00:00 [pmc-release]
AID - S0378-3782(23)00111-1 [pii]
AID - 10.1016/j.earlhumdev.2023.105815 [doi]
PST - ppublish
SO  - Early Hum Dev. 2023 Aug;183:105815. doi: 10.1016/j.earlhumdev.2023.105815. Epub 
      2023 Jul 3.